Lineage Cell Therapeutics, Inc.
Symbol: LCTX (NYSE)
Company Description:
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
- Today's Open: $1.03
- Today's High: $1.305
- Today's Low: $1.021
- Today's Volume: 7.42M
- Yesterday Close: $1.02
- Yesterday High: $1.0488
- Yesterday Low: $1
- Yesterday Volume: 838.28K
- Last Min Volume: 1.24K
- Last Min High: $1.215
- Last Min Low: $1.215
- Last Min VWAP: $1.215
- Name: Lineage Cell Therapeutics, Inc.
- Website: https://www.lineagecell.com
- Listed Date: 1992-03-05
- Location: CARLSBAD, CA
- Market Status: Active
- CIK Number: 0000876343
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $274.03M
- Round Lot: 100
- Outstanding Shares: 228.36M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-08-15 | S-8 | View |
2025-08-12 | 10-Q | View |
2025-08-12 | 8-K | View |
2025-07-17 | SCHEDULE 13G/A | View |
2025-07-03 | 4 | View |
2025-07-02 | 4 | View |
2025-07-02 | 4 | View |
2025-07-02 | 4 | View |
2025-07-02 | 4 | View |
2025-07-02 | 4 | View |
2025-07-02 | 8-K | View |
2025-06-23 | 8-K | View |
2025-06-11 | DEFA14A | View |
2025-06-09 | 8-K | View |
2025-05-13 | 10-Q | View |
2025-05-13 | 8-K | View |
2025-05-01 | 8-K | View |
2025-04-29 | ARS | View |
2025-04-29 | DEFA14A | View |
2025-04-29 | DEF 14A | View |